N-9 efficacy study
This article was originally published in The Tan Sheet
Executive Summary
Risk of HIV-1 infection was "especially high" in women who used nonoxynol-9 more than 3.5 times per day due to "an increasing frequency of lesions" caused by the spermicide, researchers report in Sept. 28 Lancet. Lut Van Damme, MD, Institute of Tropical Medicine, Antwerp, Belgium, et al., found that at low-frequency use, N-9 had no effect on HIV-1 infection. Researchers randomized 892 sex workers in South Africa, Thailand, Benin and Ivory Coast to either 3.5% N-9 gel or placebo; investigators conclude the drug "no longer has a part to play in HIV-1 prevention"...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.